Janux Therapeutics price target lowered to $150 from $200 at Cantor Fitzgerald

Cantor Fitzgerald analyst Josh Schimmer lowered the firm’s price target on Janux Therapeutics (JANX) to $150 from $200 and keeps an Overweight rating on the shares. The new data for JANX007 addresses a number of key important questions, but also leaves a handful of remaining variables and blanks to fill in, and doesn’t provide timelines for next clinical or regulatory updates, the analyst tells investors in a research note. Still, Cantor thinks the selloff is overdone, setting up for a compelling entry point.